UNSPSC 51341603: Rimantadine

This classification denotes an antiviral agent with the molecular formula C12H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0T2EF4JQTU, chemically known as 1-adamantanemethylamine, .alpha.-methyl-, hydrochloride but generally known as rimantadine, which bears US NIH Compound Identifier 5071. European Medicines Agency schedules Rimantadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10320MIG.

UNSPSC 51341603 Rimantadine is a Commodity code for a specific antiviral pharmaceutical product, yet the recent state and local opportunities tagged to this code show little alignment with rimantadine procurement itself. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, but the awarded products were Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets—neither rimantadine. Seminole County, Florida released an IFB on June 30, 2026, for Naloxone and Safe Drug Deactivation Systems, quantities of 1,900 units of Naloxone and 800 deactivation systems annually with quarterly deliveries required—again, outside the rimantadine scope. Both opportunities reflect state and county health purchasing through competitive bidding, but the mismatch between the code's nominal scope and the products actually being solicited signals that either these opportunities were misclassified at posting or rimantadine itself sees minimal recent state and local procurement activity.

State health departments and county health authorities represent the primary issuing bodies when rimantadine or similar antivirals are procured, typically through cooperative purchasing consortia such as MMCAP or direct IFB processes. Recent activity spans Illinois and Florida, though the small sample and product misalignment limit confidence in geographic characterization. Vendors pursuing this code should verify whether state pharmaceutical stockpiles, emergency preparedness programs, or specific disease-control initiatives are actively buying rimantadine; the current record offers no concrete examples of such procurement at response deadline or award.